| Style | Citing Format |
|---|---|
| MLA | Andersen JB, et al.. "The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies." Multiple Sclerosis and Related Disorders, vol. 53, no. , 2021, pp. -. |
| APA | Andersen JB, Sharmin S, Lefort M, Kochhenriksen N, Sellebjerg F, Sorensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, ... Magyari M (2021). The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies. Multiple Sclerosis and Related Disorders, 53(), -. |
| Chicago | Andersen JB, Sharmin S, Lefort M, Kochhenriksen N, Sellebjerg F, Sorensen PS, Hilt Christensen CC, et al.. "The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies." Multiple Sclerosis and Related Disorders 53, no. (2021): -. |
| Harvard | Andersen JB et al. (2021) 'The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies', Multiple Sclerosis and Related Disorders, 53(), pp. -. |
| Vancouver | Andersen JB, Sharmin S, Lefort M, Kochhenriksen N, Sellebjerg F, Sorensen PS, et al.. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies. Multiple Sclerosis and Related Disorders. 2021;53():-. |
| BibTex | @article{ author = {Andersen JB and Sharmin S and Lefort M and Kochhenriksen N and Sellebjerg F and Sorensen PS and Hilt Christensen CC and Rasmussen PV and Jensen MB and Frederiksen JL and Bramow S and Mathiesen HK and Schreiber KI and Horakova D and Havrdova EK and Alroughani R and Izquierdo G and Eichau S and Ozakbas S and Patti F and Onofrj M and Lugaresi A and Terzi M and Grammond P and Grand Maison F and Yamout B and Prat A and Girard M and Duquette P and Boz C and Trojano M and Mccombe P and Slee M and Lechnerscott J and Turkoglu R and Sola P and Ferraro D and Granella F and Shaygannejad V and Prevost J and Skibina O and Solaro C and Karabudak R and Wijmeersch BV and Csepany T and Spitaleri D and Vucic S and Casey R and Debouverie M and Edan G and Ciron J and Ruet A and Seze JD and Maillart E and Zephir H and Labauge P and Defer G and Lebrun C and Moreau T and Berger E and Clavelou P and Pelletier J and Stankoff B and Gout O and Thouvenot E and Heinzlef O and Alkhedr A and Bourre B and Casez O and Cabre P and Montcuquet A and Wahab A and Camdessanche JP and Marousset A and Patry I and Hankiewicz K and Pottier C and Maubeuge N and Labeyrie C and Nifle C and Leray E and Laplaud DA and Butzkueven H and Kalincik T and Vukusic S and Magyari M}, title = {The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies}, journal = {Multiple Sclerosis and Related Disorders}, volume = {53}, number = {}, pages = {-}, year = {2021} } |
| RIS | TY - JOUR AU - Andersen JB AU - Sharmin S AU - Lefort M AU - Kochhenriksen N AU - Sellebjerg F AU - Sorensen PS AU - Hilt Christensen CC AU - Rasmussen PV AU - Jensen MB AU - Frederiksen JL AU - Bramow S AU - Mathiesen HK AU - Schreiber KI AU - Horakova D AU - Havrdova EK AU - Alroughani R AU - Izquierdo G AU - Eichau S AU - Ozakbas S AU - Patti F AU - Onofrj M AU - Lugaresi A AU - Terzi M AU - Grammond P AU - Grand Maison F AU - Yamout B AU - Prat A AU - Girard M AU - Duquette P AU - Boz C AU - Trojano M AU - Mccombe P AU - Slee M AU - Lechnerscott J AU - Turkoglu R AU - Sola P AU - Ferraro D AU - Granella F AU - Shaygannejad V AU - Prevost J AU - Skibina O AU - Solaro C AU - Karabudak R AU - Wijmeersch BV AU - Csepany T AU - Spitaleri D AU - Vucic S AU - Casey R AU - Debouverie M AU - Edan G AU - Ciron J AU - Ruet A AU - Seze JD AU - Maillart E AU - Zephir H AU - Labauge P AU - Defer G AU - Lebrun C AU - Moreau T AU - Berger E AU - Clavelou P AU - Pelletier J AU - Stankoff B AU - Gout O AU - Thouvenot E AU - Heinzlef O AU - Alkhedr A AU - Bourre B AU - Casez O AU - Cabre P AU - Montcuquet A AU - Wahab A AU - Camdessanche JP AU - Marousset A AU - Patry I AU - Hankiewicz K AU - Pottier C AU - Maubeuge N AU - Labeyrie C AU - Nifle C AU - Leray E AU - Laplaud DA AU - Butzkueven H AU - Kalincik T AU - Vukusic S AU - Magyari M TI - The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies JO - Multiple Sclerosis and Related Disorders VL - 53 IS - SP - EP - PY - 2021 ER - |